期刊文献+

Calycosin-7-O-β-D-glucopyranoside stimulates osteoblast differentiation through regulating the BMP/WNT signaling pathways 被引量:17

Calycosin-7-O-β-D-glucopyranoside stimulates osteoblast differentiation through regulating the BMP/WNT signaling pathways
原文传递
导出
摘要 The iso fl avone calycosin-7-O-β-D-glucopyranoside(CG) is a principal constituent of Astragalus membranaceus(AR) and has been reported to inhibit osteoclast development in vitro and bone loss in vivo. The aim of this study was to investigate the osteogenic effects of CG and its underlying mechanism in ST2 cells. The results show that exposure of cells to CG in osteogenic differentiation medium increases ALP activity, osteocalcin(Ocal) m RNA expression and the osteoblastic mineralization process. Mechanistically, CG treatment increased the expression of bone morphogenetic protein 2(BMP-2), p-Smad 1/5/8, β-catenin and Runx2, all of which are regulators of the BMP- or wingless-type MMTV integration site family(WNT)/β-catenin-signaling pathways. Moreover, the osteogenic effects of CG were inhibited by Noggin and DKK-1 which are classical inhibitors of the BMP and WNT/β-catenin-signaling pathways, respectively. Taken together, the results indicate that CG promotes the osteoblastic differentiation of ST2 cells through regulating the BMP/WNT signaling pathways. On this basis, CG may be a useful lead compound for improving the treatment of bone-decreasing diseases and enhancing bone regeneration. The isoflavone calycosin-7-O-β-d-glucopyranoside (CG) is a principal constituent of Astragalus membranaceus (AR) and has been reported to inhibit osteoclast development in vitro and bone loss in vivo. The aim of this study was to investigate the osteogenic effects of CG and its underlying mechanism in ST2 cells. The results show that exposure of cells to CG in osteogenic differentiation medium increases ALP activity, osteocalcin (Ocal) mRNA expression and the osteoblastic mineralization process. Mechanistically, CG treatment increased the expression of bone morphogenetic protein 2 (BMP-2), p-Smad 1/5/8, β-catenin and Runx2, all of which are regulators of the BMP- or wingless-type MMTV integration site family (WNT)/β-catenin-signaling pathways. Moreover, the osteogenic effects of CG were inhibited by Noggin and DKK-1 which are classical inhibitors of the BMP and WNT/β-catenin-signaling pathways, respectively. Taken together, the results indicate that CG promotes the osteoblastic differentiation of ST2 cells through regulating the BMP/WNT signaling pathways. On this basis, CG may be a useful lead compound for improving the treatment of bone-decreasing diseases and enhancing bone regeneration.
出处 《Acta Pharmaceutica Sinica B》 SCIE CAS CSCD 2015年第5期454-460,共7页 药学学报(英文版)
基金 supported by the National Natural Science Foundation of China, China (No. 31400304) the Natural Science Foundation of Hubei Province, China (No. 2012FFB00303) the Youth & Middle-aged Talent Project of Hubei Province (No. Q20111005) the Science and Technology Program of Shandong Province (No. J12LL07)
关键词 BMP 发信号小径 WNT/-catenin 发信号小径 Osteoblastic 区别 Calycosin-7-O -- d-glucopyranoside ST2 房间 BMP signaling pathway WNT/β-catenin signaling pathway Osteoblastic differentiation Calycosin-7-O-β-d-glucopyranoside ST2 cells
  • 相关文献

参考文献1

二级参考文献29

  • 1Chia-Fang Wu,Deng-Chyang Wu,Hon-Ki Hsu,Ein-Long Kao,Jang-Ming Lee,Cheng-Chieh Lin,Ming-Tsang Wu.Relationship between genetic polymorphisms of alcohol and aldehyde dehydrogenases and esophageal squamous cell carcinoma risk in males[J].World Journal of Gastroenterology,2005,11(33):5103-5108. 被引量:7
  • 2P. D. Delmas,R. Eastell,P. Garnero,M. J. Seibel,J. Stepan.The Use of Biochemical Markers of Bone Turnover in Osteoporosis[J]. Osteoporosis International . 2000 (6)
  • 3Collaborative Group on Hormonal Factors in Breast Cancer.Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet,The . 1997
  • 4The WHO Study Group.Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series NO 843 . 1994
  • 5Brzezinski A,Debi A.Phytoestrogens: the "natural" selective estrogen receptor modulators?. European Journal . 1999
  • 6Adlercreutz H,Mazur W.Phytoestrogens and western diseases. Annals of Medicine . 1997
  • 7Somekawa Y,Chiguchi M,Ishibashi T,et al.Soy intake related to menopausal symptoms, serum lipids and bone mineral density in postmenopausal Japanese women. Obstetrics and Gynecology . 2001
  • 8Sanne KK,Linda K,Diederick EG,et al.Effect of soy protein containing isoflavones on cognitive function, bone mineral density, and plasma lipids in postmenopausal women: a randomized controlled trial. The Journal of The American Medical Association . 2004
  • 9Dalais F S,Ebeling P R,Kotsopoulos D,et al.The effects of soy protein containing isoflavones on lipids and indices of bone resorption in postmenopausal women. Clinical Endocrinology . 2003
  • 10Bone,HG,Greenspan,SL,McKeever,C,Bell,N,Davidson,M,Downs,RW,Emkey,R,Meunier,PJ,Miller,SS,Mulloy,AL,Recker,RR,Weiss,SR,Heyden,N,Musliner,T,Suryawanshi,S,Yates,AJ,Lombardi,A.Alendronate and estrogen effects in postmenopausal women with low bone mineral density: Alendronate/Estrogen Study Group. The Journal of Clinical Endocrinology . 2000

共引文献12

同被引文献198

引证文献17

二级引证文献92

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部